Cagri peptide dosage in clinical trials ranged from 0.3 mg to 4.5 mg weekly, while CagriSema uses 2.4 mg. Learn starting doses, titration, and safety.
Cagrilintide, nicknamed "cagri," is an investigational amylin analog given as a once-weekly subcutaneous injection. In published trials, cagri peptide dosage began at 0.25–0.3 mg per week and was titrated over several months to a maintenance dose of 2.4 mg, with 4.5 mg weekly tested as the highest monotherapy dose. Cagrilintide is not FDA-approved for human use, so no official prescribing dose exists.
What "Cagri Peptide" Actually Refers To
Cagri peptide is shorthand for cagrilintide, a long-acting synthetic version of amylin. Amylin is a hormone released alongside insulin that slows stomach emptying and signals fullness to the brain.
Novo Nordisk is developing cagrilintide both as a standalone agent and combined with semaglutide; that combination is called CagriSema. Cagrilintide is a research compound, not a prescription medication.
Cagri Peptide Dosage Used in Clinical Trials
Published phase 2 and phase 3 studies use once-weekly subcutaneous injections with gradual escalation. The table below summarizes the dose ranges that appear most often in the literature.
| Research setting | Starting dose | Maintenance dose | Frequency |
|---|---|---|---|
| Cagrilintide monotherapy (phase 2) | 0.3 mg | 1.2 mg, 2.4 mg, or 4.5 mg | Once weekly |
| CagriSema combination (phase 2–3) | About 0.25 mg cagrilintide | 2.4 mg cagrilintide plus 2.4 mg semaglutide | Once weekly |
| Typical escalation step | — | Increase roughly every 4 weeks | Once weekly |
Average weight loss in the phase 3 REDEFINE 1 trial reached about 20% of body weight at 68 weeks with CagriSema 2.4 mg/2.4 mg, which is the closest thing late-stage research has to a target cagri peptide dose. Individual results vary widely, and every trial participant was supervised by clinicians.
What "Cagri 5mg" Really Means
Most search results for cagri 5mg peptide point to research-use-only vials, not to a 5 mg dose. The number on the label describes how much lyophilized powder the vial contains in total.
At a 2.4 mg weekly dose, one 5 mg vial holds roughly two doses. That is why a cagri 5mg vial is a packaging size rather than a dosing instruction.
Research-grade vials are not tested for sterility or accurate content the way pharmaceuticals are, and self-mixing adds another layer of dosing risk.
Cagri Dosing Schedule and Titration
The cagri starting dose in every published trial was below 0.5 mg per week. From there, the schedule follows a low-and-slow pattern:
- Weeks 1–4: 0.25–0.3 mg once weekly.
- Weeks 5–8: 0.6 mg once weekly.
- Weeks 9–12: 1.2 mg once weekly.
- Week 13 and beyond: 2.4 mg once weekly, the maintenance dose used in the CagriSema program.
- Any step is held or reduced if side effects are not tolerable.
Because the powder has to be reconstituted, people who handle research peptides at home often use a peptide dosage calculator to convert vial strength and diluent volume into syringe units. Mistakes at that step are one of the most common causes of accidental overdose.
Side Effects and Safety Considerations
The most frequently reported side effects of cagrilintide are nausea, vomiting, diarrhea, constipation, and injection-site reactions. Gastrointestinal symptoms cluster in the weeks right after each dose increase.
Combining cagrilintide with a GLP-1 such as semaglutide appears to amplify those gastrointestinal effects, which is one reason the CagriSema trials escalate slowly. Anyone with a history of pancreatitis, gastroparesis, or severe kidney disease should avoid these compounds unless a physician is directly involved.
Cagrilintide is not FDA-approved for human use in the United States.
How Cagri Compares With Other Research Peptides
Cagri dosing is a weekly metabolic protocol, so it is not interchangeable with growth-hormone secretagogues. The cjc 1295 ipamorelin peptide dosage, for example, is built around pulsatile growth hormone release and looks nothing like an amylin titration.
People researching metabolic and mitochondrial compounds often compare a cagri peptide dose with plans such as aod 9604 peptide dosage for beginners or the mots-c peptide dosage protocol, and some also read up on the ss-31 peptide dosage for mitochondrial support. None of these compounds are FDA-approved, and stacking them raises the odds of overlapping side effects.
Cagri Dosage Reddit Threads: What They Get Wrong
Cagri dosage Reddit threads are anecdotal and almost never verifiable. The most common problem is confusing total vial content with the actual active dose.
- Vial size (often 5 mg or 10 mg) is not the dose.
- Reconstitution math changes with every diluent volume.
- Purity and sterility of grey-market vials are unverified.
- Reported results come from single users, not controlled studies.
Reading community logs can help you ask better questions, but they are not a substitute for clinical data or medical advice.
The Bottom Line on Cagri Peptide Dosage
Clinical research points to a weekly cagrilintide dose of 0.25–0.3 mg to start, titrated over about three months to 2.4 mg, with 4.5 mg tested as a ceiling in monotherapy studies. Cagrilintide remains investigational in the US and is not available by prescription.
Talk with a licensed healthcare professional before using any peptide, and treat online dosing charts as educational material rather than personalized medical guidance.
Frequently Asked Questions
What is the starting dose of cagri peptide?
Published trials started cagrilintide at 0.25 to 0.3 mg injected once weekly, then raised the dose roughly every four weeks. Maintenance doses in those studies reached 1.2 mg, 2.4 mg, or 4.5 mg weekly. Because cagrilintide is not FDA-approved, no official starting dose exists outside of research settings.
Is cagri 5mg a dose?
No. A cagri 5mg vial contains 5 mg of lyophilized powder in total, which is a packaging size rather than a dose. At the 2.4 mg weekly maintenance dose studied in the CagriSema program, one 5 mg vial holds about two doses.
Is cagrilintide FDA-approved?
No. Cagrilintide and the CagriSema combination are investigational in the United States and are not FDA-approved for weight loss or any other indication. The only regulated route to these drugs is an authorized clinical trial, and products sold as research chemicals are not intended for human consumption.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.